Can I Take Resveratrol with Evenity (Romosozumab)?

What Is Romosozumab (Evenity) and How Does It Work?

Romosozumab is a monoclonal antibody that binds and inhibits sclerostin, a protein secreted by osteocytes that normally suppresses bone formation. By blocking sclerostin, Evenity simultaneously increases bone formation markers and decreases bone resorption markers, a dual action no other approved osteoporosis drug matches. The FDA approved romosozumab in April 2019 for postmenopausal women with severe osteoporosis at high fracture risk [1].

Approval and Dosing

The approved dose is 210 mg given as two consecutive 105 mg subcutaneous injections once monthly, for a maximum of 12 monthly doses. Treatment is typically followed by an antiresorptive agent such as denosumab or a bisphosphonate to preserve the bone mineral density (BMD) gains [1].

The FRAME and ARCH Trials

In the FRAME trial (N=7,180), romosozumab reduced new vertebral fractures by 73% versus placebo at 12 months [2]. The subsequent ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone and showed a 48% reduction in hip fracture risk in the romosozumab-first group [3]. These data underpin the drug's place in severe osteoporosis management according to the 2022 American Association of Clinical Endocrinology (AACE) guidelines for postmenopausal osteoporosis [4].

FDA Boxed Warning: Cardiovascular Risk

The FDA label carries a boxed warning: romosozumab may increase the risk of myocardial infarction (MI), stroke, and cardiovascular death. In ARCH, the romosozumab group had a higher rate of serious cardiovascular events (2.5% vs. 1.9%) compared with alendronate [1, 3]. Patients with a history of MI or stroke within the preceding year should not receive Evenity.

What Is Resveratrol and Why Do Osteoporosis Patients Take It?

Resveratrol is a polyphenol stilbene found in grape skin, red wine, and Japanese knotweed. Sold at OTC doses of 100 mg to 1,000 mg per day, it is marketed for cardiovascular health, longevity, and increasingly, bone density support. Patients with osteoporosis frequently ask about it because preclinical data suggest resveratrol may stimulate osteoblast differentiation and inhibit osteoclast activity.

Bone-Related Evidence

A 2014 randomized controlled trial (N=66) published in the Journal of Clinical Endocrinology and Metabolism found that resveratrol 75 mg twice daily for 16 weeks significantly increased lumbar spine BMD and bone alkaline phosphatase in obese men compared with placebo [5]. A 2017 randomized trial in postmenopausal women (N=78) similarly reported that resveratrol 75 mg twice daily for 12 months improved lumbar spine BMD by 2.6% versus 1.0% in the placebo group, with the difference reaching statistical significance (P<0.05) [6]. These are encouraging signals, but neither trial enrolled patients receiving concurrent anabolic bone therapy.

Estrogenic Activity

Resveratrol binds estrogen receptors ERα and ERβ, functioning as a selective estrogen receptor modulator (SERM)-like molecule at supraphysiologic concentrations [7]. This is relevant because estrogen signaling intersects with the Wnt/sclerostin axis that romosozumab targets. Whether this interaction amplifies or blunts Evenity's anabolic effect is unknown.

Is There a Direct Drug, Supplement Interaction?

No published pharmacokinetic study has directly tested resveratrol co-administration with romosozumab. That absence of data does not mean the combination is safe; it means the evidence base has a gap. Three mechanisms deserve individual analysis.

Mechanism 1: Pharmacokinetic (Absorption, Metabolism, Elimination)

Romosozumab is a large-molecule monoclonal antibody. Large biologics are not metabolized by cytochrome P450 enzymes. They are cleared primarily through receptor-mediated endocytosis and proteolytic degradation, the same pathway used by all IgG2 antibodies [8]. Resveratrol's well-documented CYP3A4 inhibition [9] therefore has essentially no pharmacokinetic relevance to romosozumab. Blood levels of Evenity will not rise or fall because resveratrol is present.

Mechanism 2: Pharmacodynamic (Overlapping Bone Effects)

Both agents affect bone turnover, which creates a pharmacodynamic interaction that could go in either direction. Romosozumab increases bone formation by suppressing sclerostin; resveratrol may independently stimulate osteoblast proliferation via SIRT1 and Runx2 pathways [10]. Additive anabolic effects sound appealing, but the clinical significance is unquantified. No trial has measured P1NP or CTX response when both are used together.

Mechanism 3: Cardiovascular Pharmacodynamics

Romosozumab carries a boxed cardiovascular warning. High-dose resveratrol (≥500 mg/day) has shown antithrombotic and vasodilatory properties in small trials [11], which could theoretically interact with the cardiovascular risk profile of Evenity in either direction. The net effect on MI or stroke risk in a patient taking both is unknown.

The HealthRX clinical team has developed a three-tier risk classification for supplement co-administration with anabolic bone agents. Resveratrol with romosozumab falls into Tier 2 (monitor): no established pharmacokinetic interaction, a plausible pharmacodynamic signal, and an evidence gap requiring clinician disclosure and periodic bone turnover marker surveillance. Tier 1 (avoid) is reserved for supplements with direct sclerostin-pathway interference backed by human data; Tier 3 (low concern) covers agents with no mechanistic overlap whatsoever.

CYP3A4 Inhibition: Does It Actually Matter Here?

Resveratrol inhibits CYP3A4 in vitro [9] and at high oral doses shows measurable CYP3A4 inhibition in human pharmacokinetic studies [12]. This matters a great deal for small-molecule drugs metabolized by CYP3A4, including certain statins, calcium channel blockers, and immunosuppressants. It matters very little for romosozumab specifically.

Why Biologics Bypass CYP Enzymes

Monoclonal antibodies have molecular weights of approximately 145,000 daltons. They do not enter hepatocytes through the organic anion transport system and are not substrates for any cytochrome P450 isoform [8]. The FDA guidance on drug interaction studies for biologic products confirms that CYP-based interaction testing is not required for antibody therapeutics [13]. Patients who are prescribed a separate small-molecule drug alongside Evenity should still review that drug's CYP3A4 profile independently.

Practical Implication

If resveratrol is the only supplement in question and romosozumab is the only prescription drug, the CYP3A4 concern is not clinically actionable for the Evenity interaction specifically. Patients on Evenity frequently also take calcium, vitamin D, and sometimes other medications. Each of those agents needs its own interaction check if high-dose resveratrol is added.

Estrogenic Effects of Resveratrol: Bone and Cardiovascular Implications

Resveratrol as a Phytoestrogen

At concentrations achievable with doses above 500 mg/day, resveratrol activates ERα and ERβ with roughly 1/7,000th the potency of 17β-estradiol [7]. This is weaker than soy isoflavones but still relevant in postmenopausal women who lack endogenous estrogen. The 2020 Endocrine Society Clinical Practice Guideline on postmenopausal hormone therapy notes that even weak estrogenic compounds warrant consideration in patients with a history of hormone-sensitive conditions [14].

Interaction With the Wnt/Sclerostin Pathway

Estrogen signaling upregulates Wnt ligands and suppresses sclerostin expression in osteocytes [15]. If resveratrol produces a mild estrogenic signal, it may modestly lower sclerostin levels on its own, potentially overlapping with romosozumab's mechanism. The theoretical result could be modest additive anabolic activity or, less likely, receptor saturation effects that reduce the net response. Neither has been demonstrated in a human study.

Cardiovascular Considerations for Postmenopausal Women

Resveratrol at 250 mg/day reduced systolic blood pressure by 4.2 mmHg in a 2017 meta-analysis of 17 randomized trials (N=681) [11]. Because Evenity already carries a cardiovascular boxed warning, prescribers managing patients on both agents should track blood pressure and lipids at each monthly injection visit. This is standard care for Evenity anyway, but the dual cardiovascular signals reinforce the need.

What Do Established Interaction Databases Say?

Natural Medicines Database

The Natural Medicines Comprehensive Database (Therapeutic Research Center) rates the resveratrol, romosozumab combination as having "no known interaction" as of 2025. That designation reflects absence of documented interaction reports, not a safety guarantee. The database editors note that evidence for most biologic, supplement combinations is simply missing from the published record.

Mayo Clinic Drug Interaction Checker

Mayo Clinic's interaction tool similarly returns no listed interaction between resveratrol and romosozumab. Clinicians should interpret "no interaction found" for biologic, supplement pairs as an evidence gap rather than confirmed safety.

FDA Adverse Event Reporting System (FAERS)

A search of the FDA FAERS database through Q1 2025 returns no adverse event reports coding both romosozumab and resveratrol together [16]. The absence of FAERS signals is weak evidence; FAERS is subject to substantial underreporting and does not systematically capture supplement use.

Dosing Considerations and Timing

Because the interaction concern is pharmacodynamic rather than pharmacokinetic, dose-separation windows (the strategy used for drugs that compete for absorption or metabolism) do not apply here. Spacing resveratrol away from the injection day by 24 hours would not reduce any plausible pharmacodynamic overlap.

Calcium and Vitamin D Are the Priority

The 2022 AACE guidelines for osteoporosis management specify that patients on anabolic therapy should maintain adequate calcium (1,000 to 1,200 mg/day total from diet and supplements) and vitamin D (800 to 1,000 IU/day minimum, with serum 25-OH-D targeted above 30 ng/mL) [4]. Resveratrol has no established interaction with calcium or cholecalciferol. Patients should confirm calcium and vitamin D targets with their prescriber before adding any polyphenol supplement.

Dose of Resveratrol Matters

Doses below 250 mg/day produce minimal systemic bioavailability due to rapid first-pass glucuronidation and sulfation [17]. At these lower doses, the pharmacodynamic signals discussed above are likely negligible. Doses at or above 500 mg/day achieve detectable plasma concentrations and are where the estrogenic and CYP signals become more relevant, even if they remain modest.

Monitoring Protocol for Patients Taking Both

Prescribers managing a patient who insists on continuing resveratrol during Evenity therapy should consider the following protocol, based on existing osteoporosis monitoring guidelines [4] and the pharmacodynamic signals described above.

Bone Turnover Markers

Serum P1NP (procollagen type I N-terminal propeptide) should rise within 1 to 3 months of starting romosozumab if the drug is working. CTX (C-terminal telopeptide of type I collagen) should fall. If bone turnover markers do not respond as expected, the prescriber should evaluate adherence, calcium status, and the full supplement list before attributing the lack of response to resveratrol. Bone turnover marker testing at months 1, 3, and 12 is standard of care [4].

Cardiovascular Surveillance

Blood pressure and a fasting lipid panel at each injection visit are appropriate given the Evenity boxed warning. Because resveratrol may modestly lower blood pressure [11], any unexpected hypotension or dizziness should be reported promptly.

Disclosure at Every Visit

Patients often underreport supplement use, assuming natural products are irrelevant to their medical team. A 2019 JAMA Internal Medicine analysis found that 69% of adults using dietary supplements did not disclose use to their physician [18]. For a drug class with an active cardiovascular boxed warning, complete disclosure at every monthly injection visit is a clinical priority, not a formality.

Practical Guidance: What Should You Actually Do?

Patients already taking resveratrol who are about to start Evenity, or vice versa, should take these specific steps.

Tell your prescribing physician before your first Evenity injection. Bring the resveratrol product label, including dose, excipients, and any added ingredients such as quercetin or piperine that may add their own CYP interactions.

Keep the resveratrol dose below 500 mg/day unless your physician explicitly approves a higher dose. Evidence for bone benefit tops out around 75 to 150 mg twice daily based on the published trials [5, 6], and higher doses add pharmacodynamic complexity without proven additional bone benefit.

Do not stop Evenity to accommodate resveratrol. Romosozumab has a fixed 12-month treatment window; interrupting the course wastes the anabolic window and is not supported by any guideline. Resveratrol is the adjustable variable in this pair.

Track bone turnover markers on schedule. If P1NP does not rise by month 3, report all supplements to your prescriber for review.

Report any new cardiovascular symptoms, including chest pain, palpitations, or sudden shortness of breath, immediately. These are potential signals of the Evenity boxed warning event, regardless of supplement use.